Abstract:Abstract Immune-checkpoint blockade (ICB) has revolutionized cancer treatment. However, only a minority of patients achieve the long-term, durable response to ICB, and the response rates in most advanced tumors is limited to 10%-25%. The unsatisfactory overall response to ICB and the great variation in response among individuals highlight the necessity for developing predictive biomarkers and overcoming ICB resistance. A potential mode of resistance is tumor-mediated immunosuppression leading to inhibition of T cell-mediated infiltration and immunity. Here, combining single-cell and bulk transcriptomic analysis with liquid biopsy of tumor patients, we showed that S100 calcium binding protein A1 (S100A1) was closely related to ICB response, and that detecting plasma S100A1 level could help predicting the response to ICB, implying that tumor-intrinsic S100A1 may contribute to immunosuppressive tumor microenvironment (TME) and resistance to ICB. Importantly, endogenous S100a1 knockdown (S100a1KD) promoted anti-tumor immunity, conferred tumor regression, and sensitized tumors to anti-PD-1 immunotherapy in multiple syngeneic murine models. By characterizing the immune landscape of S100a1KD syngeneic murine tumor models and non-small cell lung cancer (NSCLC) clinical samples, we demonstrated a negative relationship between tumor-intrinsic S100A1 expression and infiltration of M1-like macrophage and CD8+ T cells. Single cell and spatial transcriptomic analyses, together with functional studies, have revealed that ablation of tumor-intrinsic S100A1 exerts profound impacts on the M1-like polarization of macrophages and cytotoxicity of CD8+ T cells. Moreover, the conditioned medium from S100a1KD tumor cells promoted M1 polarization of both bone marrow-derived macrophages (BMDMs) and Raw264.7 cells, which in turn reinvigorated tumor-specific T cell immunity both in vitro and in vivo. Of note, as a secreted protein, introducing recombinant S100A1 into the medium from S100a1KD tumor cells could not reverse the effects on T cells and macrophages, suggesting that these effects were independent of extracelluar S100A1 secretion and that S100A1 may act as an intracellular signaling molecule. Mechanistically, S100A1 affects deubiquitination of NF-κB through interacting with the ubiquitin-like (Ubl) domains of ubiquitin specific protease 7 (USP7), leading to upregulated granulocyte-macrophage colony-stimulating factor (GM-CSF) expression. Collectively, these data identified the S100A1/USP7/p65/GM-CSF inhibitory axis as a critical immune suppressor on M1-like macrophage polarization and T cell immunity for the promotion of tumor progression and resistance to ICB. Our findings demonstrated the potential of plasma S100A1 expression in predicting the response to ICB, and provide a rationale for combining GM-CSF and anti-PD-1 immunotherapy in tumors with high S100A1 expression. Citation Format: Yufeng Guo, Hua Bai, Jie Wang. Targeting tumor-intrinsic S100A1 augments antitumour immunity and potentiates anti-PD-1 efficacy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5368.

Downregulation of S100A11 promotes T cell infiltration by regulating cancer-associated fibroblasts in prostate cancer

E2F1 Renders Prostate Cancer Cell Resistant to ICAM-1 Mediated Antitumor Immunity by NF-κB Modulation.

Dual Effects of Targeting S100A11 on Suppressing Cellular Metastatic Properties and Sensitizing Drug Response in Gastric Cancer

S 100 A 11 influences the invasion and migration of lung cancer cells by the Notch signaling pathway

Cancer-cell derived S100A11 promotes macrophage recruitment in ER+ breast cancer

S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase

Knockout of Shcbp1 sensitizes immunotherapy by regulating α‐SMA positive cancer‐associated fibroblasts

S100A11 Promotes TGF-β1-induced Epithelial-Mesenchymal Transition Through SMAD2/3 Signaling Pathway in Intrahepatic Cholangiocarcinoma.

S100A14 inhibits cell growth and epithelial–mesenchymal transition (EMT) in prostate cancer through FAT1-mediated Hippo signaling pathway

Abstract 5368: Targeting Tumor-Intrinsic S100A1 Augments Antitumour Immunity and Potentiates Anti-Pd-1 Efficacy

Identification of miRNA signature in cancer-associated fibroblast to predict recurrent prostate cancer

EAF2 Downregulation Recruits Tumor-associated Macrophages in Prostate Cancer Through Upregulation of MIF

TGFβ1 in Cancer-Associated Fibroblasts Is Associated With Progression and Radiosensitivity in Small-Cell Lung Cancer

Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling

EFFECT OF EPITHELIAL CELLS ON S100A11 EXPRESSION IN STROMAL CELLS OF BENIGN PROSTATE HYPERPLASI

Single-cell analysis reveals the COL11A1+ fibroblasts are cancer-specific fibroblasts that promote tumor progression

Reprogramming of Cancer-Associated Fibroblasts Combined with Immune Checkpoint Inhibitors: A Potential Therapeutic Strategy for Cancers.

Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma

α11β1 Integrin is Induced in a Subset of Cancer-Associated Fibroblasts in Desmoplastic Tumor Stroma and Mediates In Vitro Cell Migration

Infiltrating T Cells Promote Prostate Cancer Metastasis Via Modulation of FGF11→miRNA‐541→androgen Receptor (AR)→MMP9 Signaling

URG11 Promotes Proliferation and Induced Apoptosis of LNCaP Cells